Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Eduardo Da Silveira

Gastroenterology San Jose, CA Medical Doctor

NPI 1326135377 CMS profile 105852

2340 Montpelier Dr, Suite A, San Jose, CA 95116

Open in the dashboard

General payments

$4,373

217 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Eduardo Da Silveira of San Jose, CA is reported in the CMS Open Payments database as having received $4,373 across 217 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 64th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $699 31
2024 General $422 23
2023 General $597 37
2022 General $609 36
2021 General $771 45
2020 General $431 23
2019 General $844 22

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Eduardo Da Silveira
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Eduardo Da Silveira were reported at $699. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Eduardo Da Silveira Gastroenterology median Middle half National median
2019 $844 $417 $126–$1,100 $163
2020 $431 $224 $74–$624 $114
2021 $771 $352 $106–$1,054 $132
2022 $609 $448 $129–$1,270 $149
2023 $597 $533 $150–$1,390 $160
2024 $422 $605 $160–$1,606 $164
2025 $699 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,661 106 payments
  2. Boston Scientific Corporation $532 3 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $398 22 payments
  4. Gilead Sciences, Inc. $319 17 payments
  5. Pfizer Inc. $179 9 payments
  6. Janssen Biotech, Inc. $140 6 payments
  7. RedHill Biopharma Inc. $132 8 payments
  8. Ardelyx, Inc. $131 5 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $112 5 payments
  10. Nestle HealthCare Nutrition Inc. $83 4 payments
  11. Other $684 32 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,883 216 payments
  2. Travel and Lodging $490 1 payment
Products named General payments · program years 2019–2025
  1. RESOLUTION CLIP $490 1 payment
  2. CREON $437 27 payments
  3. HUMIRA $412 26 payments
  4. XIFAXAN $368 20 payments
  5. RINVOQ $316 19 payments
  6. MAVYRET $304 21 payments
  7. LINZESS $291 22 payments
  8. XELJANZ $179 9 payments
  9. SKYRIZI $139 10 payments
  10. Talicia $132 8 payments
  11. Other $1,717 80 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

262

Median for Gastroenterology: 569

Drug cost

$34,191

Median for Gastroenterology: $104,976

Branded share of claims

38.9%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Linzess Linaclotide Brand 24 $25,091
Dexlansoprazole Dr Dexlansoprazole Brand 12 $2,831
Sutab Sod Sulf/Pot Chloride/Mag Sulf Brand 12 $1,933
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 24 $1,429
Pantoprazole Sodium Generic 100 $1,417
Omeprazole Generic 60 $1,069
Peg 3350-Electrolyte Sodium Chloride/Nahco3/Kcl/Peg Brand 12 $237
Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 18 $184

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 49 billing codes

Paid by Medicare

$70,814

Medicare's payments for the services billed

Medicare patients

185

Average age 75

Services billed

1,002

106 women, 79 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 45%
Arthritis 44%
Ischemic heart disease 34%
Osteoporosis 27%
Chronic kidney disease 25%
Atrial fibrillation 22%
Heart failure 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $82
$82 — —
LINZESS
  • Ironwood Pharmaceuticals, Inc $35
  • AbbVie, Inc. $35
$70 24 —
CREON
  • AbbVie, Inc. $41
$41 — —
VEGZELMA
  • Celltrion USA Inc. $28
$28 — —
MAVYRET
  • AbbVie, Inc. $20
$20 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

217 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record